Effects of affinity on binding of HER2-targeting Affibody molecules: Model experiments in breast cancer spheroids

International Journal of Oncology

Volumn 39, Issue 2, 2011, Pages 353-359

  Qvarnstrom O F ^a   Simonsson, M ^a   Carlsson, J ^b   Tran, Thuy A ^b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Affibody; Affinity; Binding; Binding site barrier; Breast cancer cells; BT474; Cell spheroids; Compound development; HER2; Penetration; Radionuclides

Indexed keywords

AFFIBODY MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN TARGETING; SPHEROID CELL;

BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; KINETICS; PROTEIN BINDING; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 79960001863     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1045     Document Type: Article

References (38)

1. Fracasso G and Colombatti M: Effect of therapeutic macromolecules in spheroids. Crit Rev Oncol Hematol 36: 159-178, 2000.
2. Carlsson J and Gedda L: Penetration of tumor therapy interesting substances in non-vasularized metastases: review of studies in multicellular spheroids. Curr Cancer Ther Rev 2: 293-304, 2006. (Pubitemid 44697127)
3. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD and Weiner LM: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750-4755, 2001. (Pubitemid 32691886)
4. Thurber GM: Kintecis of antibody penetration into tumors. In: Targeted Radionuclide Therapy. Speer TW (ed). Lippincott Williams & Wilkins, Philadelphia, ISBN 978-0-7817-9693-4 Chapter 12, pp168-181, 2011.
5. Sutherland RM and Durand RE: Radiation response of multicell spheroids - an in vitro tumour model. Curr Top Radiat Res Q 11: 87-139, 1976.
6. Carlsson J and Yuhas JM: Liquid-overlay culture of cellular spheroids. Recent Results Cancer Res 95: 1-23, 1984
7. Mueller-Klieser W: Multicellular spheroids. A review on cellular aggregates in cancer research. J Cancer Res Clin Oncol 113: 101-122, 1987
8. Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240: 177-184, 1988.
9. Mueller-Klieser W: Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol 36: 123-139, 2000.
10. Santini MT, Rainaldi G and Indovina PL: Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit Rev Oncol Hematol 36: 75-87, 2000.
11. Indovina P, Rainaldi G and Santini MT: Three-dimensional cell organization leads to a different type of ionizing radiation-induced cell death: MG-63 monolayer cells undergo mitotic catastrophe while spheroids die of apoptosis. Int J Oncol 31: 1473-1483, 2007
12. Qvarnström OF, Simonsson M, Eriksson V, Turesson I and Carlsson J: GammaH2AX and cleaved PARP-1 as apoptotic markers in irradiated breast cancer BT474 cellular spheroids. Int J Oncol 35: 41-47, 2009
13. Carlsson J and Acker H: Relations between pH, oxygen partial pressure and growth in cultured cell spheroids. Int J Cancer 42: 715-720, 1988. (Pubitemid 19008914)
14. Weinstein JN and van Osdol W: Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the 'binding site barrier'. Cancer Res 52: S2747-S2751, 1992.
15. Rudnick SI and Adams GP: Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 24: 155-161, 2009
16. Abramson V and Arteaga CL: New strategies in HER2-overexpressing breast cancere: Many combinations of targeted drugs available. Clin Cancer Res, Jan 19, 2011 [Epub ahead of print].
17. Capala J and Bouchelouche K: Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr Opin Oncol 22: 559-566, 2010.
18. Tolmachev V: Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Phar Des 14: 2999-3019, 2008.
19. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J and Ståhl SA: Selection and characterization of HER2/neu binding affibody ligands. Protein Eng Des Sel 17: 455-462, 2004 (Pubitemid 39294720)
20. Grönwall C, Sjöberg A, Ramström M, Höidén- Guthenberg I, Hober S, Jonasson P and Stahl S: Affibody-mediated transferrin depletion for proteomics applications. Biotechnol J 2: 1389-1398, 2007
21. Grönwall C, Jonsson A, Lindström S, Gunneriusson E, Ståhl S and Herne N Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J Biotechnol 128: 162-183, 2007. (Pubitemid 44960520)
22. Friedman M, Nordberg E, Höidén-Guthenberg I, Brismar H, Adams GP, Nilsson FY, Carlsson J and Stahl S: Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 20: 189-199, 2007 (Pubitemid 351321300)
23. Nord K, Nord O, Uhlén M, Kelley B, Ljungqvist C and Nygren PÅ: Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur J Biochem 268: 4269-4277, 2001. (Pubitemid 32867311)
24. Grönwall C, Snelders E, Palm AJ, Eriksson F, Herne N and Ståhl S: Generation of Affibody ligands binding interleukin-2 receptor alpha/CD25. Biotechnol Appl Biochem 50: 97-112, 2008.
25. Wikman M, Rowcliffe E, Friedman M, Henning P, Lindholm L, Olofsson S and Ståhl S: Selection and characterization of an HIV-1 gpl20-binding affibody ligand. Biotechnol Appl Biochem 45: 93-105, 2006. (Pubitemid 44362494)
26. Sandström K, Xu Z, Forsberg G and Nygren PÅ: Inhibition of the CD28-CD80 co-Stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. Protein Eng 16: 691-697, 2003.
27. Löfblom J Feldwisch J Tolmachev V, Carlsson J Ståhl S and Frejd FY Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584: 2670-2680, 2010.
28. Friedman M, Orlova A, Johansson E, Eriksson TL, Höiden-Guthenberg I, Tomachev V, Nilsson FY and Ståhl S: Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 376: 1388-1402, 2008.
29. Gunneriusson E, Nord K, Uhlén M and Nygren PÅ: Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng 12: 873-878, 1999 (Pubitemid 29533112)
30. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höiden-Guthenberg I, Widström C, Carlsson J Tolmachev V, Ståhl S and Nilsson FY: Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66: 4339-4348, 2006.
31. Nilsson FY and Tolmachev V: Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy Curr Opin Drug Discov Devel 10: 167-175, 2007
32. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J Wennborg A and Abrahmsen L: Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 7: 555-568, 2007 (Pubitemid 46524679)
33. Orlova A, Feldwisch J Abrahmsen L and Tolmachev V: Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 22: 573-584, 2007 (Pubitemid 350058993)
34. Tran TA, Rosik D, Abrahmsen L, Sandström M, Sjöberg A, Wållberg H, Ahlgren S, Orlova A and Tolmachev V: Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging 36: 1864-1873, 2009
35. Nordberg E, Friedman M, Göstring L, Adams GP, Brismar H, Nilsson FY, Ståhl S, Glimelius B and Carlsson J: Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 34: 609-618, 2007 (Pubitemid 47248288)
36. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H and Carlsson J: EGFR HER2 and HER3 expression in laryngeal primary tumours and corresponding metastases. Ann Surg Oncol 15: 1193-1201, 2008.
37. Wei Q, Shui Y, Zheng S, Wester K, Nordgren H, Nygren P, Glimelius B and Carlsson J: EGFR HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases. Implications for targeted radionuclide therapy. Oncol Rep 25: 3-11, 2011.
38. Qvarnström OF, Simonsson M, Johansson KA, Nyman J and Turesson I: DNA double strand break quantification in skin biopsies. Radiother Oncol 72: 311-317, 2004 (Pubitemid 39265385)